Specifically targeting the JAK-kinase pathway, two groups of molecules need to be considered (Figure 4): JAK and STAT inhibitors, the latest still in early clinical trials phases or pre-marketing approval for PID (58). Here, SOAT1 is linked to pelvic inflammatory disease.